{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:54:56Z","timestamp":1761173696716,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.purol.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T20:27:27Z","timestamp":1605731247000},"page":"880-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Syndrome clinique d\u2019hyperactivit\u00e9 v\u00e9sicale non neurologique\u00a0de l\u2019homme"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-6763","authenticated-orcid":false,"given":"V.","family":"Ph\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2020.09.005_bib0285","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0290","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.eururo.2011.01.031","article-title":"The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study","volume":"59","author":"Vaughan","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0295","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","article-title":"The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction","volume":"38","author":"D\u2019Ancona","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0300","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2009.07.044","article-title":"A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature","volume":"56","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0305","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0310","unstructured":"EAU Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including Benign Prostatic Obstruction (BPO), 2020. https:\/\/uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/#9."},{"key":"10.1016\/j.purol.2020.09.005_bib0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0320","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0325","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.purol.2020.09.005_bib0330","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.purol.2020.09.005_bib0335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2007.03.051","article-title":"Voiding dysfunction after radical retropubic prostatectomy: more than external urethral sphincter deficiency","volume":"52","author":"Porena","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.13078","article-title":"A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment","volume":"116","author":"Thiruchelvam","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","article-title":"Global prevalence and economic burden of urgency urinary incontinence: a systematic review","volume":"65","author":"Milsom","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0350","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0355","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0360","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/j.1464-410X.2011.10624.x","article-title":"Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1-blocker treatment for lower urinary tract symptoms","volume":"109","author":"Kaplan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0365","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(05)63949-3","article-title":"The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction","volume":"169","author":"de Nunzio","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0370","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1464-410X.2010.09359.x","article-title":"Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an \u03b1-blocker: effect of baseline prostate-specific antigen concentration","volume":"106","author":"Chapple","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0375","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lfs.2017.10.015","article-title":"Mechanisms of action for \u03b11-adrenoceptor blockers in storage symptoms with new insights into the micturition reflex","volume":"191","author":"Hattori","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.purol.2020.09.005_bib0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOU.0000000000000249","article-title":"Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?","volume":"26","author":"Cornu","year":"2016","journal-title":"Curr Opin Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.09.005_bib0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM199501123320202","article-title":"A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia","volume":"332","author":"Wasson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2020.09.005_bib0390","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.eururo.2014.01.019","article-title":"What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women","volume":"65","author":"Agarwal","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0395","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11934-008-0050-z","article-title":"Persistent detrusor overactivity after transurethral resection of the prostate","volume":"9","author":"Housami","year":"2008","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.purol.2020.09.005_bib0400","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2013.02.026","article-title":"Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study","volume":"64","author":"Lukacs","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0405","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/bmj.299.6702.762","article-title":"Outcome of elective prostatectomy","volume":"299","author":"Neal","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.purol.2020.09.005_bib0410","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)32614-9","article-title":"Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment","volume":"152","author":"Seaman Eric","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0415","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/nau.23551","article-title":"6th International consultation on incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence","volume":"37","author":"Abrams","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0420","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.urology.2005.12.036","article-title":"Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1\u00a0year of follow-up?","volume":"67","author":"Rigatti","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.purol.2020.09.005_bib0425","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.juro.2014.12.095","article-title":"Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate?","volume":"193","author":"Antunes","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0430","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1520-6777(2000)19:3<233::AID-NAU4>3.0.CO;2-M","article-title":"Can persisting detrusor hyperreflexia be predicted after transurethral prostatectomy for benign prostatic hypertrophy?","volume":"19","author":"Kageyama","year":"2000","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0435","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/iju.12482","article-title":"Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction: OAB symptom improvement post-TURP","volume":"21","author":"Zhao","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0440","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0022-5347(05)64688-5","article-title":"Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate","volume":"168","author":"Van Venrooij","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0445","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0022-5347(17)56918-9","article-title":"The results of prostatectomy: a symptomatic and urodynamic analysis of 152\u00a0patients","volume":"121","author":"Abrams","year":"1979","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0450","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1464-410X.2006.06735.x","article-title":"Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder","volume":"99","author":"Mitterberger","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0455","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.4586","article-title":"CUA guideline on adult overactive bladder","volume":"11","author":"Corcos","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.purol.2020.09.005_bib0460","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","article-title":"Bilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie b\u00e9nigne de prostate\u00a0: recommandations du CTMH de l\u2019AFU","volume":"22","author":"Descazeaud","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0465","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","article-title":"Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia","volume":"54","author":"Oelke","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0470","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.urology.2010.05.034","article-title":"Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction?","volume":"77","author":"Oh","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.purol.2020.09.005_bib0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.06.004","article-title":"Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: a noninferiority randomised controlled trial of urodynamics in 26\u00a0hospitals","author":"Drake","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0480","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/nau.22383","article-title":"Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial","volume":"33","author":"Wagg","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0485","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.urology.2007.08.008","article-title":"Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement","volume":"70","author":"Keqin","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.purol.2020.09.005_bib0490","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2147\/CIA.S115042","article-title":"Efficacy and safety of tamsulosin hydrochloride 0.2mg and combination of tamsulosin hydrochloride 0.2mg plus solifenacin succinate 5mg after transurethral resection of the prostate: a prospective, randomized controlled trial","volume":"11","author":"Shin","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.purol.2020.09.005_bib0495","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4111\/kju.2014.55.4.260","article-title":"Tolterodine to relieve urinary symptoms following transurethral resection of the prostate: a double-blind placebo-controlled randomized clinical trial","volume":"55","author":"Tehranchi","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0500","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13110","article-title":"Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes","volume":"116","author":"Habashy","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0505","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European\u2013Australian Phase 3\u00a0Trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0510","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/nau.10105","article-title":"Acupuncture reflexotherapy in the treatment of sensory urgency that persists after transurethral resection of the prostate: a preliminary report","volume":"23","author":"Ricci","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0515","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.eururo.2007.10.054","article-title":"Bladder and urethral sphincter function after radical retropubic prostatectomy: a prospective long-term study","volume":"54","author":"Giannantoni","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/21681805.2016.1250810","article-title":"Impact of postoperative phosphodiesterase type 5\u00a0inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study","volume":"51","author":"Honda","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0525","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/21681805.2016.1194460","article-title":"Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study","volume":"50","author":"Fridriksson J\u00d6","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.purol.2020.09.005_bib0530","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/j.1464-410X.2011.10623.x","article-title":"Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?","volume":"109","author":"Boettcher","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.09.005_bib0535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.urology.2007.10.023","article-title":"Role of trospium chloride in brachytherapy-related detrusor overactivity","volume":"71","author":"Bittner","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.purol.2020.09.005_bib0540","first-page":"1114","article-title":"Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy","volume":"10","author":"Hillelsohn","year":"2014","journal-title":"Urol J"},{"key":"10.1016\/j.purol.2020.09.005_bib0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/nau.22256","article-title":"GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans\u00a0\u2014\u00a0A review","volume":"32","author":"Madersbacher","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2020.09.005_bib0550","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.ijrobp.2011.04.026","article-title":"Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125i brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial","volume":"81","author":"Tsumura","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.purol.2020.09.005_bib0555","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13014-014-0302-7","article-title":"Use of alpha-1\u00a0adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil","volume":"9","author":"Tanaka","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.purol.2020.09.005_bib0280","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1089\/end.2014.0881","article-title":"Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population","volume":"29","author":"Mendez","year":"2015","journal-title":"J Endourol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720305406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720305406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:33:09Z","timestamp":1761114789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708720305406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":56,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1166708720305406"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2020.09.005","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome clinique d\u2019hyperactivit\u00e9 v\u00e9sicale non neurologique\u00a0de l\u2019homme","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}